These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 34061513)

  • 21. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
    Markianos M; Hatzimanolis J; Lykouras L
    Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism.
    Salmas RE; Yurtsever M; Durdagi S
    J Biomol Struct Dyn; 2017 Mar; 35(4):738-754. PubMed ID: 26923489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.
    Fuxe K; Borroto-Escuela DO; Tarakanov AO; Romero-Fernandez W; Ferraro L; Tanganelli S; Perez-Alea M; Di Palma M; Agnati LF
    Prog Brain Res; 2014; 211():113-39. PubMed ID: 24968778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular attributes of dopamine receptors: new potential for antipsychotic drug development.
    Hartman DS; Civelli O
    Ann Med; 1996 Jun; 28(3):211-9. PubMed ID: 8811164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
    Gogos A; Bogeski M; van den Buuse M
    Behav Pharmacol; 2008 Sep; 19(5-6):548-61. PubMed ID: 18690109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration.
    Chlan-Fourney J; Ashe P; Nylen K; Juorio AV; Li XM
    Brain Res; 2002 Nov; 954(1):11-20. PubMed ID: 12393228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dopamine D2 receptor subfamily in rat retina: ultrastructural immunogold and in situ hybridization studies.
    Derouiche A; Asan E
    Eur J Neurosci; 1999 Apr; 11(4):1391-402. PubMed ID: 10103134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
    Kapur S
    Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatic linker variations in novel dopamine D
    Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H
    Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin 5-HT
    Gener T; Tauste Campo A; Alemany-González M; Nebot P; Delgado-Sallent C; Chanovas J; Puig MV
    Neuropharmacology; 2019 Nov; 158():107743. PubMed ID: 31430459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor.
    Hjerde E; Dahl SG; Sylte I
    Eur J Med Chem; 2005 Feb; 40(2):185-94. PubMed ID: 15694653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain.
    Sakuma K; Komatsu H; Maruyama M; Imaichi S; Habata Y; Mori M
    PLoS One; 2015; 10(2):e0118510. PubMed ID: 25693194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Loc'H C; Mazière B; Paillère-Martinot ML
    Br J Psychiatry; 2001 Dec; 179():503-8. PubMed ID: 11731352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor.
    Sahlholm K; Marcellino D; Nilsson J; Ögren SO; Fuxe K; Århem P
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):149-55. PubMed ID: 24074141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probing Binding Landscapes and Molecular Recognition Mechanisms of Atypical Antipsychotic Drugs towards the Selective Targeting of D
    Appiah-Kubi P; Olotu FA; Soliman MES
    Mol Inform; 2019 Nov; 38(11-12):e1900044. PubMed ID: 31433121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
    Fejgin K; Safonov S; Pålsson E; Wass C; Engel JA; Svensson L; Klamer D
    Psychopharmacology (Berl); 2007 Apr; 191(2):377-85. PubMed ID: 17235612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments.
    Scherer H; Bedard MA; Stip E; Paquet F; Richer F; Bériault M; Rodriguez JP; Motard JP
    Cogn Behav Neurol; 2004 Mar; 17(1):32-40. PubMed ID: 15209223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.